The results of the study, published in Diabetes Technology and Therapeutics, show clinically significant improved glycemic control in people with diabetes using a smart meter and mobile application.

MALVERN, PA,, June 29, 2022 / PRNewswire / – LifeScan, a world leader in blood sugar monitoring, announced today that the peer-reviewed magazine Diabetes Technology and Therapy (DTT) publishes real evidence of improved glycemic control in people with diabetes using Bluetooth® connected glucometer with a mobile application for diabetes management, describing the results of a retrospective analysis of real data from more than 17,000 people with diabetes. A subset of these results was presented for the first time on 15you International Conference on Advanced Technology and Diabetes Treatment (ATTD) in April.

Using real data, this study aimed to find out if it uses OneTouch Reveal® mobile application with OneTouch Verio Reflect® meter – synchronized via Bluetooth® wireless technology – can maintain improved glycemic control in people with diabetes. The researchers examined anonymous blood sugar readings of more than 17,000 people with lake diabetes from LifeScan data, consisting of 4,154 people with type 1 diabetes (T1D) and 13,623 people with type 2 diabetes (T2D).

“This new real-world evidence provides additional confidence that the latest application-related blood glucose monitors offer significant clinical benefits for people with type 1 or type 2 diabetes,” he said. Oliver SchnellFounder and CEO of Sciarc GmbH, Germany. “Along with improved glycemic control, pairing blood sugar monitors with applications also allows people with diabetes to easily and accurately share data and insights remotely or in person with their healthcare providers.

A retrospective analysis found that using the OneTouch Reveal application with the OneTouch Verio Reflect meter:

  • Improved glucose readings in the range (70-180mg / dL) by + 8.1% in T1D (37% of T1D reported an improvement of + 10%) and by + 11.2% in T2D;
  • Reduced hyperglycaemia (> 180 mg / dL) by -8.5% in T1D and -11.3% in T2D; and
  • Decreased mean glucose by -14.5 mg / dL in T1D and -18.2 mg / dL in T2D.

The data also shows that spending just 11 to 20 minutes a week in the OneTouch Reveal app leads to:

  • Improved glucose readings in the range of T1D by + 8.4% and + 11.8% in T2D; and
  • Reduced hyperglycaemia (> 180 mg / dL) in T1D by -9.12% and -11.76% in T2D.

This analysis included data from people with diabetes who had blood sugar (BG) data in the pond with data for both the first 14 days using the OneTouch Verio Reflect meter with the OneTouch Reveal application (baseline) and 14 days before 90 days of use (90 days). A total of 2,069,390 and 4,550,601 BG results were available for 4,154 T1D and 13,623 T2D, respectively, over all 90 days (Cf. TABLE).

“We now know that linking a mobile health app to a glucometer, both of which are readily available, can add a clinically significant benefit to managing human diabetes,” said study co-author Dr. Elizabeth Holt, Head of Global Medical, Clinical and Safety, LifeScan. “These findings are particularly significant because more than 95% of people with diabetes who monitor their blood glucose rely on blood glucose meters compared to more expensive glucose monitors.”

Research methodology
Anonymized glucose assays and applications were extracted from a pool of LifeScan data from 4,154 people with T1D and 13,623 people with T2D. Data from their first 14 days were compared with 14 days before the 90-day time point, using paired differences within the subject.

TABLE

Time in the application

(Per week)

≤2

minutes

3 to 5
minutes

6 to 10
minutes

11 to 20

minutes

21 to 60
minutes

> 60

minutes

Type of diabetes

T1D

(n =
355)

T2D
(n =
849)

T1D
(n =
514)

T2D

(n =

1265)

T1D

(n =

655)

T2D

(n =

1728)

T1D

(n =
721)

T2D

(n =
2439)

T1D

(n =

1107)

T2D

(n =

4701)

T1D

(n =

802)

T2D

(n =

2641)

Average glucose
(mg / dL)

+0.84

-5.05

-2.48

-14.20

-5.53

-17.79

-15.11

-17.81

-9.20

-19.60

-29.36

-22.40

% readings

in scope

(70 to 180 mg / dL)

+0.16

+3.00

+2.98

+8.13

+3.45

+10.54

+8.45

+11.87

+11.03

+12.18

+14.13

+13.40

% Hyperglycemic
indications

(> 180 mg / dL)

+0.05

-3.12

-2.78

-8.43

-3.48

-10.77

-9.12

-11.76

-11.51

-12.35

-15.33

-13.57

Average

Test frequency

3.02

2.15

3.15

1.99

3.19

2.02

3.05

1.97

3.04

2.04

4.08

2.66

About OneTouch® brand manufactured by LifeScan
LifeScan is a world leader in blood sugar monitoring and digital health technologies and has a vision to create a world without limits for people with diabetes and related conditions. More than 20 million people and caregivers around the world rely on LifeScan’s OneTouch brand products to manage their diabetes. Together, LifeScan and OneTouch improve the quality of life of people with diabetes with products and digital platforms defined by simplicity, accuracy and trust. LifeScan.com and OneTouch.com.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by LifeScan Scotland Ltd. and its affiliates are licensed.

SOURCE Lifescan, Inc.

Leave a Comment

Your email address will not be published.